Gilead, Royalty Pharma acquire Emtriva rights for $525M

Gilead Sciences and Royalty Pharma have agreed to pay Emory University $525 million for the university's royalty rights to the HIV drug Emtriva. Foster City, California-based Gilead's share of that is $341 million for 65 percent of the royalty rights with the rest coming from New York-based Royalty Pharma. Emory quickly labeled the deal as the largest intellectual property rights payoff involving an American university. Emory says it will put the money to use in future scientific research and development projects.

- read this press release for more

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.